Trial

Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

Study Director
Michael Hoelscher
Start Date
/ 2021
Trial Phase
Phase II
Trial Status
all patients enrolled
Current Enrollment
75
Target Enrollment
75
Overview

75 participants will be randomized to one of five arms (15 participants per arm) to receive study medication containing bedaquiline, delamanid, and moxifloxacin with different doses of sutezolid, ranging from 0mg sutezolid up to 800mg sutezolid twice a day. Participants will be randomised and stratified by site and HIV status.

Participants will visit the study clinic on a weekly basis for sputum collection, safety monitoring and receipt of study medication.

After the completion of three months of experimental treatment participants in the experimental arms will be handed over to government TB programmes to complete their course of anti-TB treatment.

Developer Associations
Compound Associations